137 related articles for article (PubMed ID: 23891734)
1. Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.
Ge Y; Gong Z; Olson JR; Xu P; Buck MJ; Ren X
Toxicology; 2013 Oct; 312():30-5. PubMed ID: 23891734
[TBL] [Abstract][Full Text] [Related]
2. Mapping dynamic histone modification patterns during arsenic-induced malignant transformation of human bladder cells.
Ge Y; Zhu J; Wang X; Zheng N; Tu C; Qu J; Ren X
Toxicol Appl Pharmacol; 2018 Sep; 355():164-173. PubMed ID: 29966674
[TBL] [Abstract][Full Text] [Related]
3. Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis.
Eblin KE; Bredfeldt TG; Buffington S; Gandolfi AJ
Toxicol Sci; 2007 Feb; 95(2):321-30. PubMed ID: 17093206
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
5. Mitochondria are the main target organelle for trivalent monomethylarsonous acid (MMA(III))-induced cytotoxicity.
Naranmandura H; Xu S; Sawata T; Hao WH; Liu H; Bu N; Ogra Y; Lou YJ; Suzuki N
Chem Res Toxicol; 2011 Jul; 24(7):1094-103. PubMed ID: 21648415
[TBL] [Abstract][Full Text] [Related]
6. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
Wu Q; Xu W; Cao L; Li X; He T; Wu Z; Li W
J Proteome Res; 2013 Sep; 12(9):4064-73. PubMed ID: 23909948
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
8. Monomethylarsonous acid induces transformation of human bladder cells.
Bredfeldt TG; Jagadish B; Eblin KE; Mash EA; Gandolfi AJ
Toxicol Appl Pharmacol; 2006 Oct; 216(1):69-79. PubMed ID: 16806342
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
[TBL] [Abstract][Full Text] [Related]
10. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
11. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.
Farrajota K; Cheng S; Martel-Pelletier J; Afif H; Pelletier JP; Li X; Ranger P; Fahmi H
Arthritis Rheum; 2005 Jan; 52(1):94-104. PubMed ID: 15641079
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
16. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver.
Lin T; Chen H; Koustova E; Sailhamer EA; Li Y; Shults C; Liu B; Rhee P; Kirkpatrick J; Alam HB
Surgery; 2007 Jun; 141(6):784-94. PubMed ID: 17560255
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.
Faraco G; Pancani T; Formentini L; Mascagni P; Fossati G; Leoni F; Moroni F; Chiarugi A
Mol Pharmacol; 2006 Dec; 70(6):1876-84. PubMed ID: 16946032
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor phosphatase and tensin homolog protein (PTEN) is negatively regulated by NF-κb p50 homodimers and involves histone 3 methylation/deacetylation in UROtsa cells chronically exposed to monomethylarsonous acid.
Oliva-González C; Uresti-Rivera EE; Galicia-Cruz OG; Jasso-Robles FI; Gandolfi AJ; Escudero-Lourdes C
Toxicol Lett; 2017 Oct; 280():92-98. PubMed ID: 28823542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
